Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Quest Diagnostics and Scipher Medicine Join Forces to Expand Precision Medicine Availability for Rheumatoid Arthritis Patients

NextEdge Admin

05 Nov 2023

2 min 9 sec

Quest Diagnostics and Scipher Medicine have entered into a collaboration to enhance diagnostic services for individuals with rheumatoid arthritis (RA). The agreement involves Quest providing RNA extraction and next-generation sequencing services for Scipher’s PrismRA test, a blood-based molecular assay designed to predict patient response to TNF inhibitors—a common first-line treatment for RA. Additionally, Quest will handle specimen collection and transport as part of the collaboration. The financial details of the agreement were not disclosed.

TNF inhibitors are not effective in about one-third of RA patients, leading to inefficient healthcare spending and delays in obtaining effective treatment. Scipher, based in Waltham, Massachusetts, profiles approximately two dozen RNAs and combines them with patient data and results from anti-cyclic citrullinated peptide testing to identify individuals unlikely to respond to TNF inhibitor treatment. Quest, based in Marlborough, Massachusetts, will extract and sequence RNA for the PrismRA test at its laboratory.

Mark Gardner, Senior VP of Molecular Genomics and Oncology at Quest, highlighted the collaboration asaligned with Quest’s strategy and investments in genomics, particularly next-generation sequencing, and blood-specimen logistics. This collaboration enables Quest to contribute to the field of precision medicine, benefiting large, underserved patient populations. Scipher Medicine’s CEO, Alif Saleh, expressed excitement about working with Quest Diagnostics, aiming to provide patients access to the PrismRA test through this strategic partnership.